Clinical Trials Logo

Light Chain (AL) Amyloidosis clinical trials

View clinical trials related to Light Chain (AL) Amyloidosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05996406 Active, not recruiting - Clinical trials for Light Chain (AL) Amyloidosis

Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Start date: September 7, 2023
Phase: Phase 2
Study type: Interventional

Venetoclax is considered as a promising agent for light-chain (AL) amyloidosis due to the high percentage of t(11;14). Several retrospective studies showed venetoclax-based therapy could induce rapid and profound hematologic response in AL patients with favorable safety profile. As an oral agent with encouraging data, it is worth to prospectively evaluate the efficacy and safety of venetoclax in untreated AL amyloidosis patients.